AOD-9604 Peptide: Benefits, side effects, dosage details, and how it works

To call weight-loss peptides a growing market feels like a massive understatement, with brand names like Ozempic, Wegovy, Mounjaro, and Zepbound on everyone’s lips practically everywhere. But GLP-1 medications like those can cause certain discomforts, such as a loss of appetite, that many users could do without. If only there were a weight-loss drug that allowed people to eat their whole cake and crave it, too.

There might be, actually. It’s called AOD-9604, and it’s one of the relatively few restricted therapeutic peptides with a fair number of clinical studies behind it.

It has also been flagged by the U.S. Food & Drug Administration (FDA) for its potential to cause harm, given the paucity of reassuring safety data and the real risk of life-threatening immune reactions. Yet with the present push by the Secretary of Health and Human Services to “unban” currently restricted peptides, it stands some chance of becoming as widely available as the Ozempics and Zepbounds of the pharmaceutical world.

Should such an unbanning ever occur, you’d do well to be educated about AOD-9604’s therapeutic prospects. We’ve written this guide to get you informationally situated.

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

This guide to AOD-9604 is part of our large, ongoing series on therapeutic peptides, an endeavor to which we’ve devoted over 1,000 cumulative research hours and more than 30,000 words. Our work has involved reading far too many scientific sources to enumerate, as well as consulting the clinicians who prescribe peptides and the patients who use them. These efforts have allowed us to construct profiles of under-the-radar therapies that are more thoughtful and comprehensive than you’re likely to find elsewhere.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

AOD-9604 is a modified form of human growth hormone (HGH), namely its C-terminus region. Specifically, it’s a 16–amino acid fragment consisting of residues 176–191, which in lay terms means:

• It’s a synthetic part of a hormone that, in adults, helps to maintain metabolism and normal body structure.1
• It originates from a section of the HGH molecule that appears to promote fat breakdown and prevent the conversion of fatty acids to stored triglycerides2 3

A Melbourne-based biotech company called Metabolic Pharmaceuticals originally developed AOD-9604 as an anti-obesity drug — hence its name — but modified it in such a way as to impart HGH’s more desirable effects while leaving aside the potentially adverse aspects. In particular, AOD-9604 does not stimulate the production of insulin-growth factor 1 (IGF-1), as HGH does, and thus should not increase one’s risk of type 2 diabetes or tumorigenesis, as HGH can.4 5 It’s primarily selective for fat loss.

Another profound characteristic of AOD-9604 is its oral bioavailability, which places it among the relatively few therapeutic peptides that can be administered by either mouth or needle.6

Metabolic Pharmaceuticals halted further development of AOD-9604 in 2007. Two years later, it licensed AOD-9604 to another Melbourne biotech entity, Phosphagenics Limited, for use as a transdermal cosmetic preparation to reduce cellulite and subcutaneous fat.

AOD-9604 is categorically a fat-loss drug. It may be derived from HGH, but it has none of HGH’s muscle-building effects.

Its mechanism of action differs from that of better-known weight-loss peptides (e.g., GLP-1 receptor agonists) in that it’s designed to act on fat metabolism directly, with no diminishment of appetite. Such has been the case in animal studies.7

Whether AOD-9604 fulfills its fat-burning, appetite-retaining potential in humans — that remains a question.

An early 12-week multicenter clinical trial was promising. In it, 300 obese participants were randomized to receive either a placebo or one of five daily doses of AOD-9604: 1, 5, 10, 20, or 30mg. The 1mg dose group lost an average of 2.6kg, or nearly 2kg more than the placebo group. Interestingly, the 10mg dose yielded less weight loss than the minimum dose, suggesting that AOD-9604’s effects are not dose-dependent.8

A subsequent Phase 2B trial wasn’t so rosy. This one was a 24-week study with 536 participants, in which AOD-9604 was concluded not to be sufficiently efficacious.8 In the words of Metabolic Pharmaceuticals itself: “Weight loss compared to placebo at the primary and secondary endpoints ... was too low to reach statistical significance”: “less than 1kg in all dose groups,” on average.9 AOD-9604 was consequently deemed to be commercially inviable as an obesity treatment. And there you have the reason why its development was halted in 2007. The outcome of the Phase 2B trial may not have been sufficient to advance AOD-9604 to the next level of clinical testing, but it didn’t completely invalidate the drug, either. There were two important caveats:9

• All dose groups, including placebo, were subjected to a diet and weight-loss program.
• One subgroup “did show weight loss at the levels seen in the previous [12-week] trial.”

Without the variable of systematic dieting and exercise across all cohorts, the weight-loss differences between the placebo and intervention groups might have been larger — like those of the specified subgroup — and therefore statistically significant. But now, until more clinical research is undertaken, there’s no telling.

Back in 2014, researchers behind a biological assay of AOD-9604 reported that the peptide had recently “‘generally recognized as safe’ (GRAS) status, conditional on publication of preexisting safety data, for its intended use in foods, drinks, and dietary supplements.”4 Per one review, encompassing all AOD-9604 human clinical trials to date: “In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604 [sic].”7 Even in the Phase 2B trial, in which AOD-9604 failed to satisfy the primary and secondary endpoints, “the safety and tolerability of AOD9604 was excellent with no evidence of any difference from placebo [sic].”9 Recorded adverse events were almost entirely mild to moderate in severity: headaches, gastrointestinal distress, and other such common side effects.

All of that sure makes it seem as though AOD is pretty A-OK on the safety front.

But the clinical trials haven’t accounted for a major problem: immunogenicity. Indeed, as of 2026, AOD-9604 remains flagged by the Food & Drug Administration (FDA) for posing a potentially significant risk of this complication.10

Immunogenicity refers to the ability of a foreign substance, such as a medication, to trigger an immune response in the body it enters. It’s like when otherwise lovely dogs lose their minds when a delivery person steps onto the property. This person is just trying to do their job, a job that benefits you, but maybe there’s something about them — their fragrance, their gait — that your dogs don’t like.

The severity of consequences depends on the magnitude of the response. The best-case scenario is that your immune system renders the medication ineffective. Worst-case: death, such as by anaphylaxis.11

So, has AOD-9604 acquitted itself satisfactorily in clinical safety evaluations? Yes. But is AOD-9604 also capable of causing serious harm? Also yes, it would seem.

Research-grade vs. pharmaceutical-grade AOD-9604

Part of the FDA’s reasoning for flagging AOD-9604 for immunogenicity relates to “complexities with regard to peptide-related impurities and API characterization.”10 Such complexities, though, can be mitigated as long as one is using a pharmaceutical-grade form of the drug. You might also see it designated as medical-grade.

To qualify as pharmaceutical-grade, a drug must meet a high threshold of purity: around or above 99%. Free from additives, fillers, and harmful contaminants. Only then is it considered safe for humans.

The inverse of this is research-grade. A research-grade drug is exactly as it sounds: intended for laboratory use, and not suitable for human consumption. Some research-grade drugs can have purity levels as low as 60%, so you can guess at the proportion of potentially harmful contents such a product might contain. If you were to swallow or inject a research-grade form of AOD-9604, your immune system would be right to reject it.

There are at least two surefire ways to identify whether a peptide is a research- or pharmaceutical-grade substance:

• The label: If it reads something like “For research purposes only,” then it’s research-grade.
• Prescription: To obtain a pharmaceutical-grade peptide, you need a prescription from a licensed clinician. Not so with research-grade peptides.

Reading that last bit, you might be tempted to roll the dice with some research-grade AOD-9604 you find online. But please — please — don’t. We can’t imagine a circumstance in which any therapeutic peptide would be worth gambling your life on, especially when there are avenues for getting a proper prescription.

In 2026, AOD-9604 is still a restricted peptide. Though it’s somewhat accessible through a few online and brick-and-mortar clinical channels, its lack of FDA approval means that any treatment protocol can hardly be considered standard.

Nevertheless, we can deduce from available research what you might expect from treatment if you’re ever approved for an AOD-9604 prescription.

If AOD-9604 works as intended, with a direct but relatively mild lipolytic action, then the ideal candidate is someone who wants to shed a moderate amount of weight. Compared to a GLP-1 receptor agonist, the high-speed rail of weight-loss drugs, AOD-9604 is like a Honda Super Cub: better for nearer destinations or longer-term journeys. That sort of approach would be particularly suited to anyone who’d rather avoid the loss of lean muscle mass that attends the calorie intake associated with GLP-1 peptides.

Again, if it works as intended. The overall results of the Phase 2B clinical trial are reason enough to be guarded about expectations. If AOD-9604’s fat-loss effects are indeed more modest than initially believed, then any indicated candidate should view it with some measure of reservation.

Then there are the contraindicated populations, for whom AOD-9604 isn’t an option at all, or at least a dubious one. These include but aren’t necessarily limited to:

• Pregnant or breastfeeding women: Safety data being sparse already, there certainly isn’t enough research to guarantee the safety of the developing fetus or child.
• People with an active cancer diagnosis or a history of cancer: Although AOD-9604 shouldn’t have the growth hormone effects of a typical HGH derivative, there’s still some concern about a theoretical risk of tumorigenesis. Current or surviving cancer patients should discuss with their doctor whether AOD-9604 is a viable treatment for them.
• Competitive athletes: As a growth hormone fragment, AOD-9604 is presently a non-approved substance on the World Anti-Doping Agency’s Prohibited List.14 It can therefore trigger a positive drug test, disqualifying you from competition.

At this time, a peptide clinic is your best bet for obtaining pharmaceutical-grade AOD-9604. Some such clinics operate telehealth platforms, allowing you to access the drug without visiting a pharmacy. The only other online channels for the stuff are non-reputable outfits dealing in research-grade peptides, which (let us reiterate) are not fit for human consumption.

You might otherwise get it through your doctor, but your likelihood of getting a prescription may depend on their familiarity with a relatively underground medication.

As to that point, the medical community’s familiarity with AOD-9604 may grow in the near future. With the government’s push to “unban” peptides, successful reclassification of certain Category 2 drugs could cascade into a broader awareness and acceptance of presently restricted substances such as AOD-9604.

Time will tell, and as it does, we’ll update this guide accordingly.